YOKNEAM, Israel, Nov. 29 /PRNewswire-FirstCall/ -- Lumenis(R) Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that it has received FDA clearance to market the new Novus(R) 3000, a 532 nm diode-pumped solid-state (DPSS) photocoagulator.
Avner Raz, Lumenis President and Chief Executive Officer, stated, “Lumenis has provided the ophthalmic industry with innovative technology since 1970, when we introduced the world’s “first” laser photocoagulator. These lasers treat several retinal conditions that can lead to vision loss and blindness, and include conditions such as proliferative diabetic retinopathy, retinopathy of prematurity, retinal tears and detachment and retinal vein occlusion. Worldwide, estimates suggest over 30 million people suffer from these conditions, and as the population ages these numbers are expected to climb. With the addition of our Novus 3000, we once again demonstrate our commitment to helping patients and their ophthalmologists protect and preserve sight.”
Its predecessor system, the Lumenis’ Novus 2000(R), earned a solid reputation for its robust design and ease-of-use. In the ophthalmic market, the Novus 2000 is recognized as a gold standard in laser therapy for both the office and operating room, with approximately 1500 units installed. Lumenis specifically designed the Novus 3000 to improve upon this strong performance.
About the Novus 3000
With up to 3.0 watts of power through semiconductor-based technology, the Novus 3000 is ideal for treating challenging ophthalmic conditions. Instantaneous adjustments to treatment parameters can be made using the intuitive, color touch screen interface and LCD (liquid crystal display) remote control. In addition, multiple memory locations allow ophthalmologists to save and recall preferred treatment parameters. This unit comes standard with built-in storage for a laser indirect ophthalmoscope (LIO), remote control, foot switch and other accessories.
Its fully-integrated design expands treatment options by incorporating two dedicated illumination sources, which work independently with compatible LIOs and endo ocular probes. The Novus 3000 also offers a dual-fiber port, which allows two delivery devices to be attached at any time, allowing instantaneous selection between the two during busy procedures.
About the Coaxial Multicolor LIO
Lumenis also received FDA clearance to market the world’s first and only Coaxial Multicolor LIO, for the delivery of photocoagulator laser energy during ophthalmic surgery. Compatible with Lumenis’ Novus 3000 and Novus Varia, its main benefits include superior performance, integrated multi-wavelength eye safety filters and ease-of-use. This coaxial multicolor technology provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety.
About Lumenis
Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto http://www.lumenis.com
Investors: Lauri Hanover 1-866-232-6803 972-4-959-9122
The statements in this press release that are not historical facts are forward-looking statements, which are subject to risks and uncertainties. The Company’s actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company’s products, the implementation and outcome of our Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company’s international operations and the Company’s ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation (including the Wells Notice recently received in which the staff indicated its intention to recommend that a civil proceeding be brought seeking, among other things, injunctive relief and civil monetary penalties) and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
Lumenis Ltd.
CONTACT: Investors: Lauri Hanover, +1-866-232-6803, or +1-972-4-959-9122,for Lumenis
Web site: http://www.lumenis.com/
